2025年，上海资本市场在高质量发展道路上稳步前行。截至12月末，上海辖区A股上市公司总市值达10.97万亿元，占全国上市公司总市值的9.23%；前三季 度实现净利润3614.32亿元，同比增长13.34%。在复杂多变的内外部环境下，上海上市公司展现出强劲韧性和创新活力，成为实体经济高质量发展的"排头 兵"。 牛股涌现：科创板上演"速度与激情" 2025年涨幅榜见证了科创板的"造富效应"。上纬新材以1812%的全年涨幅惊艳全场，创造了"一年翻十八倍"的资本市场佳话。年度"大牛股"菲林格尔、顺灏 股份涨幅均超500%。涨幅前二十名中，科创板与创业板占据六成席位，芯片产业链的沐曦股份、东芯股份涨幅超400%，充分展现了科技创新企业的成长爆 发力。与此同时，部分传统消费与地产板块在结构调整中面临短期压力，但也为产业升级腾出了更多资源与空间。 此外，云汉芯城、超捷股份全年涨幅均超过400%，宏和科技、建发致新等上市公司全年涨幅均超过300%。 共性来看，高涨幅企业集中于硬科技、高成长赛道，科创板"造富效应"显著，反映资本市场对创新驱动型企业的强烈认可，也体现上海辖区产业结构向高端 制造、科技创新倾斜的趋势。 | 22 ...

Core Insights - The flow cytometer industry in China is projected to reach a market size of approximately 3.599 billion yuan in 2024, reflecting a year-on-year growth of 19.21% [1][9] - The industry is achieving systematic breakthroughs along three main paths: expanding detection limits, enhancing analytical dimensions, and integrating functional platforms [1][9] Industry Overview - Flow cytometers utilize lasers to detect scattered light and fluorescence signals from cells or particles in a high-speed flow state, enabling rapid multi-parameter analysis, sorting, and quantitative characterization [2] - The core principle involves hydrodynamic focusing technology that allows cells to pass through the laser detection area in a single file, capturing forward scatter (indicating cell size), side scatter (indicating internal complexity), and fluorescence signals [2] Industry Development History - The flow cytometer industry in China has evolved over 40 years, starting with the introduction of the first FACS III in 1981, leading to significant milestones in domestic production and technology breakthroughs from 2013 onwards [4] - Key advancements include the introduction of the first clinical spectral flow cytometer and the first flow mass spectrometer with IVD registration, marking significant progress in high-end equipment [4] Market Size - The flow cytometer market is experiencing a shift from laboratory to clinical applications, with a notable increase in market size and technological advancements [9] - Noteworthy innovations include the development of nano-flow technology by Fuliu Biotechnology, which extends detection limits to 24nm, and the NL-CLC spectral flow cytometer by Xiatai Biotechnology, the first clinical-approved full-spectrum product in China [9] Key Companies - Major players in the flow cytometer market include Mindray Medical, which has integrated instruments, reagents, and software into a comprehensive platform, and Fuliu Biotechnology, a leader in nano-flow technology [10][11] - Mindray's revenue for the first three quarters of 2025 was 25.834 billion yuan, a decrease of 12.38% year-on-year, with a net profit of 7.570 billion yuan, down 28.83% [11] Industry Trends - The industry is witnessing accelerated technological iteration, with a focus on high-end and intelligent advancements, including the integration of AI for data analysis and high-throughput sorting [12] - Applications are expanding beyond clinical and research fields into broader industrial and public health areas, such as environmental monitoring and food safety [13] - The domestic production process is accelerating, driven by supply chain security and the need for local alternatives, reshaping the competitive landscape [14]

Core Viewpoint - Hanon Medical, the first domestic company to achieve the localization of ECMO systems, is facing significant financial challenges despite its technological breakthroughs and plans for an IPO to raise funds for production and sales capabilities [2][4][11]. Financial Performance - Hanon Medical reported a revenue of 37.35 million yuan in the first half of 2025, with a net loss of 82.27 million yuan, indicating a narrowing loss trend [4][5]. - Cumulative losses since 2022 have exceeded 670 million yuan, with the company still in a state of continuous loss [4][5]. - The company has invested approximately 434 million yuan in R&D since its establishment, with R&D expenses significantly exceeding revenue, reaching 138.66% of revenue in the first half of 2025 [6][7]. Market Position and Challenges - The company’s ECMO system has been adopted by over 140 hospitals, including top-tier institutions, but the high price point of over one million yuan per unit has hindered revenue scaling [5][9]. - Hanon Medical faces intense competition in the ECMO market, dominated by foreign brands, and is under pressure from a declining willingness of hospitals to purchase new equipment [8][10]. - The company relies heavily on a limited number of medical trading companies for sales, which poses risks if these intermediaries face operational difficulties [9][10]. Funding and Future Prospects - The IPO aims to raise 1.062 billion yuan, with 500 million yuan allocated for R&D center construction and 250 million yuan for working capital, highlighting the company's reliance on external funding [7][11]. - The company’s ability to transition from a technology leader to a commercially successful entity will depend on resolving its profitability issues and navigating market challenges effectively [11].

内容概况：我国的步进电机在二十世纪七十年代初开始起步，七十年代中期至八十年代中期为成品发展 阶段，新品种和高性能电机不断开发，为行业奠定了坚实基础。在永磁材料、半导体技术及计算机技术 持续进步的推动下，步进电机如今已在众多领域中实现广泛应用。作为全球最重要的工业制造基地之 一，中国拥有庞大且增长迅速的步进电机市场。近年来，伴随中国制造业的转型升级，市场对步进电机 的需求持续增加，同时国内消费者对产品品质与性能的要求也日益提升。在此背景下，中国政府通过制 定科技创新规划和技术标准化规范等一系列政策措施，积极支持并引导行业技术进步与健康发展。数据 显示，中国步进电机行业市场规模已从2016年的17.39亿元稳步增长至2024年的38.9亿元，年复合增长率 达到10.59%。展望未来，步进电机市场空间广阔，预计产业规模将进一步扩大，2025年市场规模有望 达到41.24亿元。 上市企业：江苏雷利（300660）、鼎智科技（920593）、鸣志电器（603728）、兆威机电（003021）、 三协电机（920100）、雷赛智能（002979）、宝钢股份（600019）、首钢股份（000959）、鞍钢股份 （00089 ...

证券研究报告——晨会聚焦 2026 年 1 月 7 日 | 市场指数 | | | | --- | --- | --- | | 指数名称 | 收盘价 | 涨跌% | | 上证综指 | 4083.67 | 1.50 | | 深证成指 | 14022.55 | 1.40 | | 沪深 300 | 4790.69 | 1.55 | | 中小 100 | 8593.43 | 1.83 | | 创业板指 | 3319.29 | 0.75 | | 行业表现（申万一级） | | | | | --- | --- | --- | --- | | 指数名称 | 涨跌% | 指数名称 | 涨跌% | | 有色金属 | 4.26 | 通信 | (0.77) | | 非银金融 | 3.73 | 美容护理 | 0.20 | | 基础化工 | 3.12 | 银行 | 0.48 | | 国防军工 | 3.08 | 食品饮料 | 0.50 | | 综合 | 2.89 | 家用电器 | 0.52 | 资料来源：万得，中银证券 中银晨会聚焦-20260107 ■重点关注 【基础化工】电子材料行业 2026 年度策略*余嫄嫄 范琦岩 赵泰。受益于下 ...

作为国家级专精特新"小巨人"企业，无锡市晶源微电子股份有限公司（以下简称"晶源微电子"）自2003年成立以来，始终专注于高性能模拟和数模混合集 成电路领域的深耕细作。如今，这家历经二十载发展的半导体企业正加速冲刺资本市场，在中信证券的专业辅导下稳步推进首次公开发行股票并上市工 作，朝着"中国领先的半导体集成电路设计企业"愿景持续迈进。 从技术实力与研发创新来讲，晶源微电子展现出国家级高新技术企业的硬核实力。公司拥有一支技术实力雄厚、经验丰富的研发团队，具备基于Bipolar、 CMOS、BiCMOS、BCD多工艺平台的产品设计能力，构建了完善的研发体系与创新机制。截至公开信息显示，公司累计拥有专利信息220条、商标信息 18条以及著作权信息2条，仅2025年就有多款发明专利获得授权，涵盖压控振荡电路、自适应信号锁存电路、高压静电防护结构等多个核心技术领域。这 些技术成果不仅彰显了公司的研发创新能力，更有效提升了产品的核心竞争力，助力公司在细分领域形成技术壁垒。同时，公司还建成了江苏省模拟集成 电路IP核工程技术研究中心、市级工业企业设计中心两大研发机构，先后荣获工信部CSIP"十年中国芯"优秀设计企业、全国优 ...

Core Viewpoint - The demand for high-end PCB products is significantly increasing due to the expansion of AI computing power, leading to a notable rise in PCB equipment demand [4]. Group 1: PCB Equipment Market Overview - The global PCB specialized equipment market is projected to reach $10.8 billion by 2029, with a CAGR of 8.7% from 2024 to 2029 [5]. - Key equipment segments in 2024 include drilling (21%), exposure (17%), inspection (15%), and electroplating (7%) [5]. - The demand for mechanical and laser drilling equipment is expected to coexist, with domestic manufacturers likely to capture high-end mechanical drilling equipment replacement demand [5]. Group 2: Specific Equipment Insights - In the exposure equipment sector, LDI equipment is a critical competitive area, with market share concentrated among leading companies [5]. - The electroplating equipment sector features diverse technological routes, with domestic firms holding an advantage in vertical continuous electroplating [5]. - The inspection field is becoming increasingly competitive, moving towards 3D and online capabilities [5]. Group 3: Emerging Trends and Innovations - The introduction of NVIDIA's Rubin architecture is expected to reshape the demand and landscape for drilling equipment and drill bits [6][7]. - The anticipated use of M9-grade copper-clad laminates in PCBs will significantly increase processing difficulty and costs, leading to a projected multi-fold increase in demand for AI PCB drill bits [7]. - The short-term market for tungsten-cobalt alloy-coated drill bits will remain dominant for processing M9 materials, while the commercialization of diamond drill bits is still pending [7].

Group 1 - High-temperature alloys are critical materials in aerospace engines, gas turbines, and nuclear power equipment, directly influencing thrust, efficiency, and lifespan of high-end equipment [2][3] - The high-temperature alloy industry in China is accelerating due to the "Two Aircraft Special Project," the mass production of the C919 aircraft, breakthroughs in gas turbine localization, and the "dual carbon" strategy [2][4] - Nickel-based alloys dominate the market, accounting for 80% of demand, with deformation alloys making up 75% of production by 2024 [3][21] Group 2 - The production of high-temperature alloys in China increased from 19,000 tons in 2017 to 49,000 tons in 2023, with a CAGR of 17.1%, while demand rose from 21,000 tons to 52,000 tons, with a CAGR of 16.8% [4][34] - By 2024, production is expected to reach 57,000 tons, with aerospace (55%) and power generation (20%) as the main demand sectors [4][34] - The annual average demand for high-temperature alloys is projected to exceed 56,500 tons from 2025 to 2030, driven by factors such as the replacement of aircraft engines and the localization of commercial aircraft [4][39] Group 3 - The global high-temperature alloy market is expected to exceed $30 billion by 2025, with China's market projected to reach 120 billion yuan, growing at over 15% annually [5] - Domestic production capacity is expected to exceed 60,000 tons by 2025, but there remains a 30% supply gap for high-end products [5][6] - The domestic localization rate is anticipated to rise from less than 40% in 2020 to about 65% by 2025, supported by policies under the 14th Five-Year Plan [5][6] Group 4 - The industry is characterized by a "technology-driven, strong players" dynamic, with an expected annual compound growth rate of 15% from 2025 to 2027 [6] - Leading companies are achieving breakthroughs in niche markets, with notable revenue growth reported by companies such as Western Superconducting and Steel Research [6][8] - The competitive landscape shows a high concentration in upstream and a diverse midstream, with major players in the upstream segment like Fushun Special Steel [5][6] Group 5 - High-temperature alloys are primarily used in aerospace, accounting for over 50% of total demand, and are critical for the performance of advanced aircraft engines [26][34] - The demand for high-temperature alloys in gas turbines is expected to exceed 151,000 tons from 2025 to 2030, driven by domestic and international power generation needs [40][44] - The military sector is also a significant driver, with domestic naval gas turbines reaching international standards, enhancing the capabilities of the People's Navy [62]

点击 最 下方 关注《材料汇》 ， 点击"❤"和" "并分享 添加 小编微信 ，寻 志同道合 的你 正文 先进制程的成本暴涨体现在设计和建厂两端： 制程从平面 FET 演进至 FinFET、Nanosheet 后，量子效应、测试验证难度激增，导致设计成本指数级上 升；5nm 工厂投资是 20nm 的 5 倍，中小企业已无力承担先进制程的资本开支。 图表清晰展示，随着关键尺寸微缩，设计成本从 65nm 的 2800 万美元飙升至 2nm 的 7.25 亿美元，建厂投入同步激增。 这背后意味着 行业集中度将向头部晶圆厂倾斜，而先进封装通过 "混合制程" 让中小企业无需依赖先进制程即可参与高端芯片设计，成为行业格局重构的 关键变量。 芯粒异构集成的核心是 "按需分配工艺" ——CPU 等核心部件用 3nm 先进制程，I/O、模拟电路用成熟制程，最大化性价比。 与单片集成相比，其优势集中在 "IP 复用""良率改善""缩短上市时间"： IP 复用避免重复设计，研发周期缩短 30% 以上；小芯片良率远高于大芯片，拆 分后整体良率叠加，实际生产成本大幅降低；独立验证机制减少试错成本，快速响应市场需求。 这背后是 芯片行业 ...

中国证监会于1月5日披露，湖南长步道光电科技股份有限公司（以下简称"长步道"）已正式启动向不特 定合格投资者公开发行股票并在北京证券交易所上市的辅导备案，辅导机构为中金公司。 自2010年成立以来，长步道始终聚焦于技术要求较高的工业镜头业务，持续推进技术研发与产品创新。 目前，公司产品已成功应用于新能源、半导体、光伏、显示面板、3C电子等多个高端制造领域，助力 相关行业实现自动化检测、精密测量与智能识别，为客户提供高性价比的国产化光学解决方案。 此次启动北交所上市辅导，标志着长步道在调整资本市场路径后，继续借助证券化步伐加速发展，有望 进一步强化研发投入、扩大生产规模，提升在工业镜头领域的国产替代能力与市场竞争力。 值得关注的是，长步道此前曾冲刺科创板。公司于2023年6月30日递交科创板上市申请并获受理，但在 未回复首轮问询的情况下，于同年12月19日主动撤回申请，上市进程终止。此次转战北交所，公司表示 主要系基于战略规划调整及业务发展的综合考量。 作为国内工业镜头领域的领先企业，长步道深耕行业十余年，已形成涵盖标准工业镜头（FA镜头）、 线扫镜头（LS镜头）、大靶面镜头、远心镜头、特种工业镜头等在内的完整 ...